Wellbeing Digital Sciences Inc.

Equities

MEDI

CA94946J1084

Healthcare Facilities & Services

End-of-day quote NEO Exchange Other stock markets 06:00:00 2023-04-03 pm EDT			5-day change	1st Jan Change
0.015 ^CAD	+200.00%		-.--%	-.--%

2023	Cardinal Group Companies LLC entered into an agreement to acquire KGK Science Inc. from Wellbeing Digital Sciences Inc. for $2 million.	CI
2023	Wellbeing Digital Sciences Inc.'s Wholly Owned Subsidiary KGK Sciences Inc Begins Recruitment in First-Of-Its-Kind Health Canada Approved Psilocybin Trial	CI

KetamineOne Capital Limited Reports Earnings Results for the First Quarter Ended October 31, 2021

December 15, 2021 at 04:12 pm EST

KetamineOne Capital Limited reported earnings results for the first quarter ended October 31, 2021. For the first quarter, the company reported sales was CAD 1.99 million. Net loss was CAD 9.23 million compared to CAD 0.60581 million a year ago. Basic loss per share from continuing operations was CAD 0.08 compared to CAD 0.01 a year ago.

Latest news about Wellbeing Digital Sciences Inc.

Cardinal Group Companies LLC entered into an agreement to acquire KGK Science Inc. from Wellbeing Digital Sciences Inc. for $2 million.	23-06-15	CI
Wellbeing Digital Sciences Inc.'s Wholly Owned Subsidiary KGK Sciences Inc Begins Recruitment in First-Of-Its-Kind Health Canada Approved Psilocybin Trial	23-04-18	CI
KGK Science Inc. Awards an Institution Wide Cannabis Research License for Their New Facility by Health Canada	22-12-08	CI
Wellbeing Digital Sciences Inc. Appoints Mohammad Sharifi to Board of Directors	22-11-22	CI
Wellbeing Digital Sciences Inc. Announces Management Changes	22-11-18	CI
Nova Mentis Enters into Research Services Contract with KGK Science for Phase II A Clinical Trial	22-11-17	CI
Wellbeing Digital Signs LOI Manage Additional Clinics	22-10-04	CI
Wellbeing Digital Sciences Inc. Reports Earnings Results for the Full Year Ended July 31, 2022	22-09-13	CI
Wellbeing Digital Sciences Inc. Reports Earnings Results for the Fourth Quarter Ended July 31, 2022	22-09-13	CI
Wellbeing Digital Sciences Inc. Appoints Najla Guthrie to the Benzinga Psychedelic Advisory Council	22-08-30	CI
Wellbeing Digital Seeks Acquisitions	22-08-18	CI
Wellbeing Digital Sciences Inc. Announces Change of Financial Year End from July 31 to October 31	22-08-11	CI
Wellbeing Digital Sciences Appoints Natalie Dolphin as VP of Marketing and Investment Relations	22-06-21	CI
Wellbeing subsidiary KGK Science Announces Positive Clinical Trial Results of GJ 191 (JointAlive(R)) Supplementation in Treating OA	22-06-16	CI
Wellbeing Digital Sciences Announces the Appointment of Terry Zimaro as Chief Financial Officer	22-06-15	CI
Wellbeing Digital Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2022	22-06-14	CI
Wellbeing Digital Sciences Inc. Announces Resignation Joseph Ramelli as Chief Financial Officer	22-05-27	CI
Wellbeing Digital Sciences Inc. Appoints Michael Ho as the New Medical Director, Effective May 2, 2022	22-05-03	CI
Pathway Health Corp. (TSXV : PHC) entered into a memorandum of understanding to acquire Assets of Wellbeing Digital Sciences Inc and IRP Health Ltd	22-04-20	CI
Wellbeing Digital Sciences Reports Sales Results for the Second Quarter of Fiscal 2022	22-03-18	CI
Wellbeing Digital Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2022	22-03-16	CI
Wellbeing Digital Sciences Announces CEO Changes, Effective March 31, 2022	22-03-07	CI
Wellbeing Digital Sciences Inc Delivers its First IV Ketamine Treatment Under the Inpatient KITE Program	22-02-15	CI
KetamineOne Capital Limited has Changed its Name to Wellbeing Digital Sciences Inc	22-01-24	CI
Ketamine One Becomes Exclusive Ketamine Treatment Provider to Victoria Wellness	22-01-17	CI

Chart Wellbeing Digital Sciences Inc.

Duration

Period

More charts

Company Profile

Wellbeing Digital Sciences Inc. is a Canada-based mental healthcare company. The Company is focused on the development and implementation of clinical treatment solutions, including psychedelic medicine and digital therapeutics, as supported by clinical research. It operates through three segments: Wellbeing & IRP; KGK Science and Mindscape. It operates medical clinics across North America to help its patients access plant-based medicines, psychedelics, and other forms of mental health care, all of which have the potential to heal them of their physical and/or emotional pain. Its subsidiaries include Mindscape Ketamine & Infusions Therapy LLC, KGK Science Inc. and Integrated Rehab and Performance Ltd. It is also supported by a network of North American clinics that provide therapies and other types of treatment to patients as well as through a contract research organization that offers clinical trials services with a focus on nutraceutical and emerging health care products.

Sector

Healthcare Facilities & Services

More about the company

Income Statement Evolution

More financial data

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
WELLBEING DIGITAL SCIENCES INC.	-.--%	1.79M
CVS HEALTH CORPORATION	-15.00%	84.87B
HCA HEALTHCARE, INC.	+11.05%	83.08B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+10.92%	29.4B
LABORATORY CORPORATION OF AMERICA HOLDINGS	-12.38%	16.72B
FRESENIUS SE & CO. KGAA	-3.06%	16.4B
QUEST DIAGNOSTICS INCORPORATED	-1.87%	15.04B
EUROFINS SCIENTIFIC SE	-3.97%	11.88B
FRESENIUS MEDICAL CARE AG	-1.42%	11.88B
PURE HEALTH HOLDING	-31.75%	11.86B

Other Healthcare Facilities & Services